Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens

The comparison does not establish that PJP has a durable edge: trailing outperformance may reflect a favorable pharma factor regime, while backward-looking beta and drawdown can understate discontinuous risks from trial outcomes, patent exposure, or pricing policy. The key exposure is not simply “concentrated versus diversified”: PJP is more sensitive to pharma-specific earnings revisions and drug-cycle leadership; RSPH dilutes that exposure but its equal weighting can leave it more exposed to weaker or smaller constituents and rebalance effects. The cited GLP-1 theme is not enough to underwrite PJP—verify current holdings and weights, since the leaders of a theme need not be material contributors to this ETF.

Near term, there is no compelling directional trade from the supplied data alone. Over 1–3 months, relative returns will likely hinge on pharma earnings revisions, policy headlines, and pipeline news; over 6–18 months, patent erosion and replacement-product launches matter more than the funds’ fee gap. The 18bp annual fee difference is secondary to constituent returns, turnover, and trading spreads. A low historical beta is not protection against event gaps. The contrarian risk is chasing PJP’s realized performance just as its underlying leadership reverses; conversely, a broad-sector allocation could lag if pharma momentum and earnings estimates continue to strengthen.